Company Overview of MYR GmbH
MYR GmbH is a biotechnology company that develops Myrcludex B, a drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta infection. Its product inhibits the essential HBV receptor and prevents the spread of HBV in the liver. The company was founded in 2010 and is based in Burgwedel, Germany.
Founded in 2010
49 5139 894379
49 513 9806 894 0
Key Executives for MYR GmbH
MYR GmbH Key Developments
Similar Private Companies By Industry
|4 Animals AlsterScience GmbH||Europe|
|Acousia Therapeutics GmbH||Europe|
|Across Barriers GmbH||Europe|
|Actinodrug Pharmaceuticals GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact MYR GmbH, please visit www.myr-pharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.